ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2026
Longitudinal FeNO monitoring in pediatric asthma: association of FeNO and its trajectory patterns with asthma control status.
Article in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundFractional exhaled nitric oxide (FeNO) is a non-invasive biomarker of type 2 inflammation with potential for personalized asthma management. However, the longitudinal patterns of FeNO and their association with childhood asthma control remain insufficiently characterized.
methodsThis cohort study enrolled children with newly diagnosed asthma from Shanghai Children's Medical Center. Participants underwent baseline assessments and serial FeNO measurements at diagnosis and at 3-month intervals over 12 months. Asthma control was assessed at 12 months using Global Initiative for Asthma (GINA) criteria. Longitudinal trajectories of FeNO were identified using group-based trajectory modeling (GBTM). Associations of time-specific FeNO levels and FeNO trajectory group with uncontrolled asthma at 12 months were analyzed using logistic regression.
resultsAmong 142 children (mean age 6.92 ± 2.08 years; 71.1% male), 125 (88.0%) achieved controlled asthma and 17 (12.0%) had uncontrolled asthma at 12 months. Elevated FeNO at 3 and 12 months was significantly associated with increased odds of uncontrolled asthma after adjusting for covariates. Longitudinal FeNO levels showed two distinct trajectories: low-stable (80.3% of participants) and high-rising (19.7%). Compared with the low-stable group, the high-rising group had significantly older age, later wheezing onset, higher serum total immunoglobulin E (IgE) and eosinophil percentages (all p < 0.05). Children in the high-rising trajectory group had higher odds of uncontrolled asthma (OR = 5.86; 95% CI: 1.28-29.57; p = 0.025).
conclusionsElevated FeNO levels during follow-up and a high-rising FeNO trajectory are associated with uncontrolled asthma at 12 months in children with newly diagnosed asthma. Longitudinal FeNO monitoring may help identify children at increased risk of poor asthma control and support more individualized asthma management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.